India’s Wockhardt Selling Two Foreign Subsidiaries To Raise Funds
This article was originally published in PharmAsia News
Wockhardt of India is putting Negma Laboratories, a France-based subsidiary up for sale, one of at least two Wockhardt plants to be disposed of. The sales are part of a plan to raise funds to repay investors, according to an equity fund executive. Wockhardt also plans to sell its Irish subsidiary. The fund executive said the sales have become necessary because the company has not been able to work out deals with potential investors. (Click here for more
You may also be interested in...
One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.
Sun Pharma and its US Taro subsidiary have further criticized a recent CMS policy proposal that would see Medicare Part B drugs approved under the US hybrid 505(b)(2) pathway reimbursed at a lower rate applicable to multiple source products.
An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.